Valuation: Gyre Therapeutics, Inc.

Market Cap 779M 695M 648M 589M 1.11B 75.06B 1.12B 7.83B 3.05B 38.31B 2.93B 2.86B 123B P/E 2026 *
-18.4x
P/E 2027 * -31.3x
Enterprise Value 779M 695M 648M 589M 1.11B 75.06B 1.12B 7.83B 3.05B 38.31B 2.93B 2.86B 123B EV / Sales 2026 *
7.12x
EV / Sales 2027 * 5.58x
Free-Float
25.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-2.46%
Current month-2.59%
1 month-0.42%
3 months-1.65%
6 months+0.28%
Current year+1.13%
1 week 7
Extreme 7
7.43
1 month 6.46
Extreme 6.46
7.74
Current year 5.44
Extreme 5.44
9.14
1 year 5.44
Extreme 5.44
9.42
3 years 5.44
Extreme 5.44
30.4
5 years 5.44
Extreme 5.44
30.4
10 years 5.44
Extreme 5.44
30.4
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Director

40,000 0.0359%
8/3/26 Free

Director

40,000 0.0359%
6/10/26 Free

Director

40,000 0.0412%
Change 5-day change 1-year change 3-year change Capi.($)
-2.45%-2.46%-2.72% - 779M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.28%-1.30%+3.45%+34.36% 48.3B
-3.34%-2.48%+328.08%+696.33% 44.51B
-0.47%-2.01%+28.56%+32.69% 43.8B
+1.91%+0.64%+6.70%+111.42% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
+0.41%-0.89%-7.10%-12.16% 24.53B
Average +0.73%-0.37%+47.56%+125.44% 39.43B
Weighted average by Cap. +1.29%-0.50%+56.94%+133.85%

Financials

2026 *2027 *
Net sales 110M 97.68M 91.01M 82.82M 156M 10.55B 157M 1.1B 428M 5.38B 411M 402M 17.3B 140M 125M 116M 106M 199M 13.44B 200M 1.4B 545M 6.86B 524M 513M 22.06B
Net income -38.85M -34.66M -32.29M -29.38M -55.34M -3.74B -55.75M -390M -152M -1.91B -146M -143M -6.14B -32.3M -28.81M -26.85M -24.43M -46.01M -3.11B -46.35M -324M -126M -1.59B -121M -119M -5.1B
Net Debt - -
Projected Income Statement - Annual - Gyre Therapeutics, Inc.
Logo Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
Employees
625
Date Price Change Volume
26-10-06 US$7.140 -2.86% 47,092
26-10-05 US$7.350 +3.38% 181,458
26-10-02 US$7.110 +1.57% 163,747
26-10-01 US$7.000 -4.50% 139,998
26-09-30 US$7.330 +0.14% 159,793
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Gyre Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.350USD
Average target price
18.67USD
Spread / Average Target
+153.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gyre Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GYRE Stock